Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by
Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128,
an oral treatment for chronic HCV infection, is in a 4-week Phase 1
clinical trial in combination with Pegasys plus Copegus through a strategic
collaboration with Roche. Racivir, which is being developed for the
treatment of HIV in combination with other approved HIV drugs, has
completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Alan Roemer, Vice President
Investor Relations & Corporate Communications
Office: +1 (609) 613-4125
Pharmasset "Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995: Statements in this press release regarding
our business that are not historical facts are "forward-looking statements"
that involve risks and uncertainties, including without limitation the risk
that adverse events could cause the cessation or delay of any of the
ongoing or planned clinical trials and/or our development of our product
candidates, the risk that we cannot enroll enough patients for the Phase 3
registration clinical trial for clevudine, the risk that our collaboration
with Roche will not continue or will not be successful and the risk that
any one or more of our product candidates will not be successfully
developed and commercialized. For a discussion of these risks and
uncertainties, any of which could cause our actual results to diff
|SOURCE Pharmasset, Inc.|
Copyright©2008 PR Newswire.
All rights reserved